Is Amphastar Pharmaceuticals (AMPH) Fully Priced After Strong Q3 Earnings And Q4 Guidance?

ملخص مفصل

Amphastar Pharmaceuticals (AMPH) is back in focus after reporting third quarter results and issuing fresh fourth quarter guidance, with management projecting high single digit…

Amphastar Pharmaceuticals (AMPH) is back in focus after reporting third quarter results and issuing fresh fourth quarter guidance, with management projecting high single digit sales growth compared with last year.

At a share price of $28.87, Amphastar Pharmaceuticals has had a strong run recently, with a 30 day share price return of 10.83% and a 90 day move of 38.07%. The 1 year total shareholder return of 9.48% contrasts with a much weaker 3 year total shareholder return that declined 48.60%, which suggests that the latest earnings beat and guidance are being treated by investors as a potential turn in momentum rather than a continuation of the past three years.

Scan for other potential momentum turns by comparing Amphastar Pharmaceuticals with 32 high quality undervalued stocks that pair recent earnings strength with solid balance sheets.

The share price sits above analyst targets, yet Amphastar Pharmaceuticals still screens at a heavy discount to some fair value estimates. Is the market rightly cautious after a tough three years, or mispricing a cleaner earnings story?

On the Simply Wall St analyst consensus Narrative, Amphastar Pharmaceuticals screens with a fair value of $24.50 compared with a last close of $28.87. That gap reflects a view that the current share price bakes in more optimism than the modelled cash flows support at a 7.236% discount rate.

Still, if newer respiratory and injectable therapies keep supporting revenue and the insulin biosimilar program scales as planned, Amphastar Pharmaceuticals could challenge that narrative of overvaluation.

Find out about the key risks to this Amphastar Pharmaceuticals narrative.

The fair value Narrative pegs Amphastar Pharmaceuticals at $24.50, yet on simple earnings multiples the picture looks different. The stock trades on a P/E of 12.4x, compared with 20x for peers and 14.7x for the broader US pharmaceuticals group, while the fair ratio sits at 13.3x.

To see how this pricing gap could close in either direction, and…

مطلع المقال، مقتطف من Yahoo Finance. لقراءة المقال كاملًا، افتحه على موقع الناشر.